<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Giardiasis: Treatment and prevention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Giardiasis: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Giardiasis: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Luther A Bartelt, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Giardia lamblia</em> (also known as <em>Giardia duodenalis</em> or <em>Giardia intestinalis</em>) is a flagellated protozoan parasite [<a href="#rid1">1</a>]. <em>G. lamblia</em> causes both epidemic and sporadic disease; it is an important etiology of waterborne and foodborne diarrhea and daycare center outbreaks [<a href="#rid2">2-4</a>].</p><p>Issues related to the treatment and prevention of giardiasis will be reviewed here. The life cycle, epidemiology, clinical manifestations, and diagnosis of giardiasis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5723.html" rel="external">"Giardiasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">INITIAL TREATMENT</span></p><p class="headingAnchor" id="H295956593"><span class="h2">Nonpregnant adults and children</span></p><p class="headingAnchor" id="H1101223335"><span class="h3">Asymptomatic individuals</span><span class="headingEndMark"> — </span>The goal of treatment in asymptomatic individuals is to prevent spread of infection to other, more vulnerable patient populations. We suggest treatment of asymptomatic individuals in the following circumstances (<a class="graphic graphic_algorithm graphicRef139552" href="/z/d/graphic/139552.html" rel="external">algorithm 1</a>) [<a href="#rid5">5-7</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Individuals in group settings with risk for transmission to others (such as a child in a daycare setting, health care workers, or nursing facility worker)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised individuals</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Household contacts of immunocompromised individuals (especially those with hypogammaglobulinemia or cystic fibrosis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Household contacts of pregnant individuals</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Food handlers</p><p></p><p>In the absence of risk for transmission, it is reasonable to forgo treatment of asymptomatic individuals. We discuss the lack of data demonstrating benefit in asymptomatic low-risk patients and the toxicities of therapy and then come to a decision whether to treat through shared decision making with the patient. When treating asymptomatic infection, the approach is the same as for symptomatic individuals. (See <a class="local">'Symptomatic individuals'</a> below.) </p><p class="headingAnchor" id="H1497305522"><span class="h3">Symptomatic individuals</span><span class="headingEndMark"> — </span>The approach to treatment of symptomatic individuals (eg, diarrhea, abdominal cramping, bloating) with giardiasis includes antimicrobial therapy and supportive care (eg, correction of fluid and electrolyte abnormalities resulting from the diarrhea). (See  <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/6129.html" rel="external">"Oral rehydration therapy"</a>.) </p><p>However, since some infections are self-limited, it is reasonable to forgo antimicrobial treatment for patients with mild symptoms and/or contraindications to antimicrobial therapy. Main agents for the treatment of giardiasis are <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a>, <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>, and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>. Our approach to selecting among them depends on age (<a class="graphic graphic_algorithm graphicRef139552" href="/z/d/graphic/139552.html" rel="external">algorithm 1</a>). </p><p class="headingAnchor" id="H2910417079"><span class="h4">Individuals ≥3 years old</span><span class="headingEndMark"> — </span>For individuals ≥3 years old, we suggest <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a>. A single dose is associated with high efficacy (&gt;90 percent) and is better tolerated than other agents [<a href="#rid8">8</a>]. If tinidazole is not available, <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> is a highly effective alternative agent but requires a three-day course. <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is also effective, but may be associated with more side effects. Other alternatives are discussed elsewhere. (See <a class="local">'Alternative agents'</a> below.)</p><p>Dosing is summarized in the table (<a class="graphic graphic_table graphicRef61810" href="/z/d/graphic/61810.html" rel="external">table 1</a>) [<a href="#rid9">9,10</a>]. <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">Tinidazole</a> is available only in tablet form. For children unable to swallow tablets, the tablets may be crushed by a pharmacist and mixed with flavored syrup; the suspension should be shaken before use and is good for seven days at room temperature [<a href="#rid11">11</a>]. Side effects of tinidazole include metallic taste (17 percent), nausea, and headache (&lt;3 percent) [<a href="#rid12">12-14</a>]. The drug has been associated with a disulfiram-like effect, so alcohol consumption should be avoided [<a href="#rid5">5,15,16</a>]. To minimize gastrointestinal side effects, tinidazole should be taken with food [<a href="#rid7">7</a>]. </p><p><a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">Tinidazole</a> may be more effective than alternative agents, although there is substantial heterogeneity across studies [<a href="#rid12">12</a>]. In a network meta-analysis of 60 randomized trials that included over 6000 children and adults with giardiasis, tinidazole was associated with higher rates of parasitologic cure compared with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (relative risk [RR] 1.23, 95% CI 1.12-1.35) and <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> (RR 1.35, 95% CI 1.21-1.50), although risk of bias among studies was high [<a href="#rid8">8</a>]. In another open-label, randomized trial including more than 160 children with giardiasis, parasitologic cure at 10 days was achieved more frequently with tinidazole 50 mg/kg as a single dose compared with <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> 7.5 mg/kg twice daily for three days (90 versus 78 percent) [<a href="#rid13">13</a>]. As a single-dose regimen, tinidazole is more effective and better tolerated than metronidazole [<a href="#rid14">14</a>]. </p><p class="headingAnchor" id="H49436128"><span class="h4">Individuals between 1 and 3 years old</span><span class="headingEndMark"> — </span>For individuals between ages one and three years, we favor <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>. The safety of <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> has not been established in patients less than three years of age. <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is an alternative, although it may be associated with more side effects. Additionally, in the United States, nitazoxanide is the only drug with US Food and Drug Administration approval for giardiasis for this age group. Other alternatives are discussed elsewhere. (See <a class="local">'Alternative agents'</a> below.)</p><p>Dosing is summarized in the table (<a class="graphic graphic_table graphicRef61810" href="/z/d/graphic/61810.html" rel="external">table 1</a>) [<a href="#rid17">17</a>]. <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">Nitazoxanide</a> is available in liquid and tablet form [<a href="#rid7">7</a>]. Side effects of nitazoxanide include nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, yellow eyes, dysuria, and discolored (bright yellow) urine [<a href="#rid16">16</a>].</p><p>The efficacy of <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> in various trials ranges from 78 to 85 percent [<a href="#rid13">13,16,18-21</a>]. For example, in a randomized study of 110 children with giardiasis treated with a five-day course of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> or three-day course of nitazoxanide, symptoms resolved within seven days in the majority of children (80 versus 85 percent; 5.4 percent difference, 95% CI -8.9 to 19.7 percent) [<a href="#rid18">18</a>]. In addition, nitazoxanide may be effective in treating other intestinal parasites (eg, cryptosporidiosis and amebiasis) and may shorten the duration of diarrhea attributed to infection even when no pathogen is detected [<a href="#rid7">7,21-24</a>].</p><p class="headingAnchor" id="H4260770442"><span class="h4">Individuals &lt;12 months old</span><span class="headingEndMark"> — </span>For individuals less than 12 months of age, we suggest <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> due to lack of safety data with use of <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> and <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> in this patient population.  </p><p>Dosing is summarized in the table (<a class="graphic graphic_table graphicRef61810" href="/z/d/graphic/61810.html" rel="external">table 1</a>) [<a href="#rid7">7</a>]. Oral <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is available only in tablet form; an oral suspension may be prepared by a compounding pharmacy. Side effects associated with metronidazole include metallic taste, nausea, gastrointestinal discomfort, and headache [<a href="#rid14">14,25</a>]. Less common effects include leukopenia, dark urine, paresthesias, and dizziness [<a href="#rid5">5</a>]. </p><p>The efficacy of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> for treatment of giardiasis is 75 to 100 percent [<a href="#rid16">16,25,26</a>]. For example, in a randomized study of 110 children with giardiasis treated with a five-day course of metronidazole or three-day course of <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>, symptoms resolved within seven days in the majority of children (80 versus 85 percent) [<a href="#rid18">18</a>]. Adverse events were common (in approximately 75 percent) but were mild and transient and did not result in treatment discontinuation. </p><p class="headingAnchor" id="H1328173299"><span class="h4">Alternative agents</span><span class="headingEndMark"> — </span>Alternative agents with activity against giardiasis are summarized below. Selection depends upon availability, need for concurrent treatment of other intestinal parasites, and drug intolerances.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Albendazole</strong><strong> or </strong><strong>mebendazole</strong> – <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> and <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">mebendazole</a> have comparable efficacy (80 to 100 percent) for treatment of giardiasis but are not as effective as <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> [<a href="#rid16">16,25,27-35</a>]. However, since both drugs also have activity against other parasites that may occur as coinfections in patients with <em>Giardia </em>(such as hookworm and <em>Ascaris</em>), they may be a reasonable option for certain individuals [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent1">Dosing is summarized in the table (<a class="graphic graphic_table graphicRef61810" href="/z/d/graphic/61810.html" rel="external">table 1</a>). <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> comes in tablets; <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">mebendazole</a> comes in tablets or suspension. Both drugs should be taken with food to increase bioavailability [<a href="#rid5">5</a>]. Albendazole or mebendazole have fewer side effects than <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> or <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid15">15,32,33,36</a>]; these include abdominal pain, nausea, vomiting, and increased hepatic transaminases. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> is not as effective in eradicating <em>Giardia</em> compared with <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a>. In an open-label, randomized study of 113 children with giardiasis treated with a one-time dose of tinidazole or a three-day course of albendazole, parasitologic cure rate was higher in the tinidazole-treated group (96 versus 50 percent) [<a href="#rid37">37</a>]. In another randomized study of 122 children with giardiasis who were treated either with a one-time dose of tinidazole or three doses of <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">mebendazole</a>, parasitologic cure rate at seven days was higher in the tinidazole group (82 versus 64 percent) [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paromomycin</strong> – The reported efficacy of <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> for treatment of giardiasis is 55 to 90 percent; dosing is summarized in the table (<a class="graphic graphic_table graphicRef61810" href="/z/d/graphic/61810.html" rel="external">table 1</a>) [<a href="#rid5">5</a>]. It is a reasonable alternative agent for treatment of mild giardiasis in settings where other agents are contraindicated, such as pregnancy (see <a class="local">'Pregnant and lactating individuals'</a> below). It is not recommended for treatment of severe giardiasis since the lack of systemic absorption limits its efficacy. Side effects include nausea, increased gastrointestinal motility, diarrhea, and abdominal pain [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Furazolidone</strong> – The efficacy of furazolidone for treatment of giardiasis is approximately 80 percent; dosing is summarized in the table (<a class="graphic graphic_table graphicRef61810" href="/z/d/graphic/61810.html" rel="external">table 1</a>) [<a href="#rid5">5,7,16,39</a>]. Furazolidone is no longer available in the United States. Side effects include gastrointestinal upset, headache, hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency, and neuropathy [<a href="#rid5">5,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quinacrine</strong> – The efficacy of quinacrine for treatment of giardiasis is &gt;90 percent; dosing is summarized in the table (<a class="graphic graphic_table graphicRef61810" href="/z/d/graphic/61810.html" rel="external">table 1</a>). However, use of quinacrine for treatment of giardiasis is reserved for refractory cases due to the drug’s adverse effects and the drug should not be used in pregnant individuals [<a href="#rid38">38,40,41</a>]. In a multicenter prospective study of 106 European travelers with nitroimidazole refractory giardiasis, quinacrine (100 mg three times a day for five days) yielded higher clinical (81 percent) and parasitologic (100 percent) cure rates compared with <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> plus <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> combination therapy [<a href="#rid41">41</a>]. Availability of quinacrine is extremely limited (it is not commercially available) but can be compounded at some pharmacies. Side effects of quinacrine including nausea, vomiting, dizziness, headache, psychosis, yellow-orange discoloration of the skin and mucous membranes, hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency, and increased risk for cancer of the reproductive tract [<a href="#rid5">5,7,16,39,41</a>]. (See <a class="local">'Refractory giardiasis after repeated trials of preferred agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secnidazole</strong> – <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">Secnidazole</a> may be administered as a single dose for treatment of adults with giardiasis. Cure rates of 80 to 100 percent have been observed, but the drug has been associated with abdominal pain, nausea, anorexia, glossitis, and stomatitis [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ornidazole</strong> – Ornidazole may be administered as a single daily dose in children and adults [<a href="#rid42">42,43</a>]. It has similar efficacy to <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> and is available in some countries outside the United States.</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Pregnant and lactating individuals</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnant individuals in the first trimester</strong> – For treatment of pregnant individuals with mild giardiasis who are able to maintain hydration and nutrition, it is reasonable to delay therapy until at least the second trimester to minimize the risk of adverse drug effects for the fetus [<a href="#rid5">5</a>]. If treatment is necessary during the first trimester, we suggest <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> since it is associated with limited systemic absorption [<a href="#rid5">5</a>] (see <a class="local">'Alternative agents'</a> above). <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">Tinidazole</a> can cross the placenta and should not be used during first trimester. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnant individuals in the second and third trimester</strong> – During the second and third trimesters, we suggest <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> for mild disease and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> for severe disease due to more intrapartum safety data available for these agents compared with <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> or <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>. Paromomycin should not be used to treat severe disease due to lack of published efficacy in this setting. In cases of refractory disease or when metronidazole cannot be used, use of tinidazole or nitazoxanide may be appropriate. Clinicians should discuss the risks and benefits of treatment with tinidazole and nitazoxanide with the patient given the limited safety data with these agents. (See <a class="local">'Symptomatic individuals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lactating individuals</strong> – For treatment of lactating individuals with giardiasis, reasonable agents include <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a>, <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a>, <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>, or <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, and the choice among them may be informed by need to interrupt breastfeeding. Women treated with paromomycin need not interrupt lactation; if tinidazole, nitazoxanide, or metronidazole is used, we suggest brief lactation interruption. The suggested duration of lactation interruption is 72 hours for tinidazole and 12 to 24 hours for metronidazole [<a href="#rid44">44</a>]. The optimal duration of breastfeeding cessation in women treated with nitazoxanide is uncertain [<a href="#rid45">45</a>]. Low levels of tizoxanide, a nitazoxanide metabolite, appear in breastmilk following a single dose. At the concentrations measured, tizoxanide is not expected to cause adverse effects in infants (especially &gt;2 months of age).</p><p></p><p class="headingAnchor" id="H16"><span class="h1">PERSISTENT OR RECURRENT SYMPTOMS</span></p><p class="headingAnchor" id="H3117238297"><span class="h2">Expected response to therapy</span><span class="headingEndMark"> — </span>Among patients with acute giardiasis who are treated appropriately, symptoms typically resolve within five to seven days, and parasites usually clear from the stool in this time frame [<a href="#rid5">5,46,47</a>]. In low-prevalence settings, successful therapy also results in rapid clearance of <em>Giardia </em>DNA from stool [<a href="#rid47">47</a>]. In those who had chronic symptoms (&gt;8 weeks) associated with <em>Giardia</em> prior to treatment, symptoms may take several months to resolve [<a href="#rid48">48</a>]. </p><p>There is no need to repeat the stool examination to check for parasite clearance for individuals whose symptoms resolve within the expected time frame based on acute versus chronic presentation. </p><p class="headingAnchor" id="H3164880684"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Persistent symptoms may be attributable to persistent infection related to treatment failure, ongoing exposure, inadequate adherence, or immunosuppression. Recurrent symptoms after initial response to therapy may be due to persistent infection or reinfection. More often, however, persistent or recurrent symptoms occur as a result of noninfectious causes; these include postinfectious lactose intolerance, other absorptive deficiencies, and irritable bowel syndrome. </p><p>Patients with recurrent or persistent symptoms should undergo the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Repeat stool examination (stool antigen or polymerase chain reaction [PCR]) for detection of <em>Giardia</em> [<a href="#rid5">5</a>]. A negative stool PCR is suggestive of parasite clearance [<a href="#rid47">47</a>]; in such cases, management should focus on postinfectious sequelae or pursuit of an alternative diagnosis. Stool microscopy is not recommended as it lacks adequate sensitivity to rule out ongoing infection in patients with persistent symptoms [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/5723.html" rel="external">"Giardiasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for potential sources of reinfection (eg, review of the exposure history, risk factors, and hygiene practices). (See  <a class="medical medical_review" href="/z/d/html/5723.html" rel="external">"Giardiasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Routes of transmission'</a>.)</p><p></p><p>For individuals with &gt;1 recurrence or for those with history suggestive of immunocompromise (eg, other recurrent infections), we perform evaluation for underlying immunodeficiency by conducting a thorough history and exam, checking quantitative immunoglobulin (Ig) levels (eg, hypogammaglobulinemia, X-linked agammaglobulinemia, IgA deficiency), and reviewing the presence of immunosuppressive drug use and/or immunocompromising conditions (eg, hematologic malignancy, organ transplantation, or HIV). Patients with underlying immunodeficiency and/or epidemiologic exposure to parasitic infections also warrant evaluation for other pathogens including intestinal helminths [<a href="#rid31">31,49</a>]. (See  <a class="medical medical_review" href="/z/d/html/5949.html" rel="external">"Approach to the child with recurrent infections"</a> and  <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">"Ascariasis"</a> and  <a class="medical medical_review" href="/z/d/html/5721.html" rel="external">"Hookworm infection"</a> and  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis"</a> and  <a class="medical medical_review" href="/z/d/html/5692.html" rel="external">"Enterobiasis (pinworm) and trichuriasis (whipworm)"</a>.) </p><p>Individuals with negative repeat stool examination should undergo evaluation for noninfectious causes of symptoms. (See <a class="local">'Persistent symptoms with negative stool assay'</a> below.)</p><p class="headingAnchor" id="H3028506308"><span class="h2">Management</span><span class="headingEndMark"> — </span>Individuals with an established diagnosis of recurrent or persistent giardiasis (based on repeat diagnostic testing) warrant a repeat course of antimicrobial therapy. </p><p class="headingAnchor" id="H2904628796"><span class="h3">Recurrence of disease (diagnostically proven)</span><span class="headingEndMark"> — </span>In individuals in whom symptoms resolved weeks or months prior to recurrence, we favor treatment with <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> or <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>, even if they had received the same agent previously [<a href="#rid7">7</a>]. The dose and duration recommended for initial treatment are appropriate for recurrent disease. In patients initially treated with a short course of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (single-dose or five-day course) who cannot take tinidazole or nitazoxanide, it is reasonable to give a longer course of metronidazole (for example, extending the duration to 10 days). </p><p>In individuals with more than one recurrence, referral to an infectious diseases specialist for management is warranted. </p><p class="headingAnchor" id="H2497678733"><span class="h3">Minimal or no response to initial antimicrobial therapy</span><span class="headingEndMark"> — </span>In individuals who had minimal or no response to initial therapy, we favor treatment with an antimicrobial agent from a different class. As an example, patients treated initially with a nitroimidazole (<a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> or <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>) may be treated with <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>, which has demonstrated activity against nitroimidazole-refractory infections [<a href="#rid39">39,50,51</a>]. </p><p class="headingAnchor" id="H153887032"><span class="h3">Refractory giardiasis after repeated trials of preferred agents</span><span class="headingEndMark"> — </span>In individuals who repeatedly fail therapy with nitroimidazoles (eg, <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> or <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>), <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>, or an alternative agent (eg, <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a>), we favor treatment with the following combination regimen [<a href="#rid50">50,52,53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> (15 mg/kg per day orally, maximum dose 400 mg) <strong>PLUS</strong> <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (15 mg/kg orally per day divided in three doses, with a maximum dose of 250 mg per dose) for five days [<a href="#rid5">5,29,54-56</a>]. In an observational study of 38 adults with metronidazole-refractory giardiasis, albendazole in combination with metronidazole was effective in achieving parasitologic cure in 79 percent of cases [<a href="#rid54">54</a>]. </p><p></p><p>Quinacrine-containing regimens are potential alternative options, but these should only be used for refractory cases given the substantial side effects. Such regimens include the following (see <a class="local">'Alternative agents'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Quinacrine (6 mg/kg per day orally divided in three doses; maximum dose 100 mg per dose) for five days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">Tinidazole</a> (50 mg/kg orally as a single dose; maximum dose of 2 g) <strong>PLUS </strong>quinacrine (6 mg/kg per day orally divided in three doses; maximum dose 100 mg per dose) for 14 to 21 days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> (15 mg/kg orally per day divided in three doses; maximum dose of 250 mg per dose) <strong>PLUS</strong> quinacrine for 14 to 21 days [<a href="#rid46">46</a>]</p><p></p><p>A sequential approach with a trial of more than one regimen may be necessary if symptoms persist; in such cases, consultation with a specialist in infectious diseases and evaluation for underlying immunodeficiency is warranted [<a href="#rid7">7,13</a>]. (See <a class="local">'Evaluation'</a> above.)</p><p>Use of quinacrine has been shown to be effective for patients not responding to nitroimidazole monotherapy; however, its use is limited by side effects and availability [<a href="#rid40">40,41,57,58</a>] (see <a class="local">'Alternative agents'</a> above). Data on use of combination regimens for treatment of recurrent or persistent giardiasis are limited. <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">Tinidazole</a> or <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> combined with <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> has not been studied.</p><p class="headingAnchor" id="H70010434"><span class="h3">Persistent symptoms with negative stool assay</span><span class="headingEndMark"> — </span>In some patients, poor weight gain and gastrointestinal symptoms (including bloating, diarrhea, and nausea) may persist after completion of treatment and documentation of negative stool assays. In most of these cases, <em>Giardia </em>infection has cleared and additional antimicrobial therapy is not warranted. We recommend a trial of a lactose-free diet given that lactase deficiency occurs in 20 to 40 percent of patients with giardiasis and may linger for several weeks after treatment [<a href="#rid16">16</a>]. </p><p>If suspicion for persistent giardiasis remains and the sensitivity of the stool test used is low (eg, stool microscopy), gastroenterology consultation regarding endoscopy to evaluate for ongoing presence of trophozoites in the small intestine may be warranted. Such evaluation is also useful for evaluation of other small intestinal/malabsorption pathologies [<a href="#rid59">59-62</a>]. (See  <a class="medical medical_review" href="/z/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/5881.html" rel="external">"Approach to chronic diarrhea in children &gt;6 months in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/5878.html" rel="external">"Persistent diarrhea in children in resource-limited settings"</a>.)</p><p class="headingAnchor" id="H673762574"><span class="h1">ANTIMICROBIAL RESISTANCE</span><span class="headingEndMark"> — </span>Antimicrobial resistance testing is not routinely available in most clinical settings. Data regarding local antimicrobial resistance prevalence and its clinical relevance are thus too sparse to influence treatment recommendations. In general, presence of persistent or recurrent treatment-refractory symptoms should prompt suspicion for antimicrobial resistance; however, the management approach is largely empiric. The approach for such cases is discussed above. (See <a class="local">'Persistent or recurrent symptoms'</a> above.)</p><p><em>Giardia </em>isolates vary in their in vitro<em> </em>susceptibility to <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (both are nitroimidazoles) and resistance to these agents has been observed [<a href="#rid25">25,38,63-68</a>]. Increasing rates of nitroimidazole-refractory infection in some settings has raised concern regarding spread of nitroimidazole resistance [<a href="#rid38">38,63-65,69</a>]. However, in vitro<em> </em>drug resistance does not correlate consistently with clinical outcome [<a href="#rid69">69</a>]. Thus far, <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> resistance appears restricted to laboratory strains [<a href="#rid70">70</a>]. </p><p class="headingAnchor" id="H17"><span class="h1">COUNSELING AND PREVENTION</span><span class="headingEndMark"> — </span>Measures for prevention of giardiasis include counseling, infection control interventions, and water purification. There is no vaccine available for prevention of giardiasis. </p><p class="headingAnchor" id="H682951315"><span class="h2">Counseling on reducing transmission</span><span class="headingEndMark"> — </span>Individuals with giardiasis should be counseled on avoiding settings with risk for transmission to others (such as childcare centers, school, or recreational water venues) until asymptomatic for 48 hours [<a href="#rid1">1</a>]. They should also be counseled to diligently adhere to hand hygiene with soap and water (preferred over hand hygiene with alcohol-based hand disinfection [AHD]) while symptomatic. Anal receptive and oral-anal sex should be avoided while actively infected. </p><p class="headingAnchor" id="H4065648710"><span class="h2">Counseling to prevent infection</span><span class="headingEndMark"> — </span>To avoid becoming infected with <em>Giardia</em>, patients should be counseled to avoid drinking water or eating food that may be contaminated and swallowing water while swimming in recreational water areas. <em>Giardia</em> cysts are eliminated by boiling tap water at least one minute [<a href="#rid71">71,72</a>]. Water purification tools for hikers and campers include water filtration iodination and chlorination; iodine-based treatments are more effective than chlorine-based treatments [<a href="#rid73">73</a>]. </p><p>Patients should be counseled to avoid contact with stool during sex, to use a barrier during oral-anal sex, and to wash hands after handling a condom used during anal sex and after touching the anus or rectal area. These are general recommendations for prevention of gastrointestinal pathogens, regardless of whether partners are known to have infection. </p><p>The type of <em>Giardia</em> that infects humans is usually not the same type that infects dogs or cats. Issues related to prevention of transmission from pets are discussed on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fparasites%2Fgiardia%2Fprevention-control-pets.html&amp;token=PtnzWoK6zgG3RO7fnJ96Loa0HTutwDHkehNYFYw%2FF7EyR%2Bpml%2BKOlA7lVgkR1BcTNsmzqqCPJnjKrbJxyAsQD6Mxmx8zqw5ZaSmueT%2F%2Fw9c%3D&amp;TOPIC_ID=6024" target="_blank">United States Centers for Disease Control and Prevention website</a>.</p><p class="headingAnchor" id="H3574292159"><span class="h2">Infection control</span><span class="headingEndMark"> — </span>In health care and other institutional settings, patients with giardiasis who are in diapers or are incontinent should be placed on contact precautions for the duration of illness (in addition to standard precautions) [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Contact precautions'</a>.) </p><p>Attention to hygiene is important for preventing person-to-person transmission of giardiasis. Strict handwashing, care with diaper disposal, and treatment of symptomatic children can prevent the spread of giardiasis. Hand hygiene with soap and water is preferred over hand hygiene with AHD. AHD is effective against trophozoites passed in the stool but is not effective against the cyst form that survives in the environment (<a class="graphic graphic_figure graphicRef100761" href="/z/d/graphic/100761.html" rel="external">figure 1</a>).</p><p>Issues related to environmental cleaning and disinfection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/101613.html" rel="external">"Infection prevention: General principles", section on 'Health care environment: Cleaning and disinfection'</a>.)</p><p>Diagnosis of giardiasis should prompt notification of the local health department (this is usually performed by the laboratory) [<a href="#rid2">2,74</a>].</p><p class="headingAnchor" id="H3135960357"><span class="h2">Resource-limited settings</span><span class="headingEndMark"> — </span>Due to the low infectious dose necessary to cause <em>Giardia </em>infection, access to clean water, sanitation, and hygiene are critical to reduce <em>Giardia </em>community prevalence. In resource-limited settings, inadequate water, sanitation, and hygiene results in endemic pediatric <em>Giardia </em>infection. Individual sanitation and hygiene measures result in the greatest reduction in <em>Giardia </em>infection in these settings [<a href="#rid75">75</a>]. Other tools for prevention of giardiasis in resource-limited settings include breastfeeding and nutrient supplementation, although nutrient supplementation without improvements in sanitation and hygiene may be of limited benefit [<a href="#rid75">75</a>]. There is no role for mass drug administration to reduce <em>Giardia </em>carriage in resource-limited settings [<a href="#rid76">76</a>].</p><p>Breastfeeding is protective against giardiasis in nursing infants in endemic areas [<a href="#rid77">77-79</a>]. In one study including more than 150 infants in Egypt, exclusively breastfed infants had a lower incidence of giardiasis than infants who were not exclusively breastfed [<a href="#rid79">79</a>]. </p><p>Nutrition should be optimized based on World Health Organization nutrition guidance for specific age groups [<a href="#rid80">80,81</a>]. Adequate nutrition can help protect against giardiasis. Zinc and <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> have been associated with a protective effect against giardiasis among children in resource-limited settings [<a href="#rid78">78</a>]. In one randomized study in Brazil (in a region where approximately one-third of children had at least mild vitamin A deficiency) of 79 children age 2 months to 9 years of age, those who received vitamin A had significantly fewer new <em>Giardia</em> infections compared with those treated with placebo over a three-year period (for example, 0 versus 19 percent at one month post-treatment) [<a href="#rid82">82</a>]. In another study in Mexico City, treatment of 707 children age 6 to 15 months with zinc, vitamin A, or both was associated with decreased incidence of giardiasis [<a href="#rid83">83</a>].</p><p>However, some nutrient supplements may adversely alter the course of illness. In a randomized study including more than 600 children age 6 to 60 months in Tanzania, administration of a multi-nutrient supplement increased diarrheal symptoms among children with giardiasis (hazard ratio 2.03, 95% CI 1.24-3.32) [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H1384369812"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109942.html" rel="external">"Society guideline links: Acute diarrhea in adults"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15896.html" rel="external">"Patient education: Giardia (The Basics)"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3995.html" rel="external">"Patient education: Giardia (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic individuals</strong> – Treatment for most asymptomatic individuals is not necessary. We suggest treatment of asymptomatic infection in the following individuals to reduce transmission risk (<a class="graphic graphic_algorithm graphicRef139552" href="/z/d/graphic/139552.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals in group settings with risk for transmission to others (such as a child in a daycare setting, health care workers, or nursing facility worker) </p><p class="bulletIndent2"><span class="glyph">•</span>Immunocompromised individuals</p><p class="bulletIndent2"><span class="glyph">•</span>Household contacts of immunocompromised individuals (especially those with hypogammaglobulinemia or cystic fibrosis)</p><p class="bulletIndent2"><span class="glyph">•</span>Household contacts of pregnant individuals, and</p><p class="bulletIndent2"><span class="glyph">•</span>Food handlers </p><p></p><p class="bulletIndent1">Regimen selection is the same as in symptomatic individuals. (See <a class="local">'Asymptomatic individuals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment of symptomatic individuals</strong> – For individuals ≥3 years old, we suggest single-dose <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> over other agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If unavailable, <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> is similarly highly effective but warrants a three-day course. <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is less effective and may be associated with more side effects. For younger children, some options do not have sufficient safety data for use. Thus, for individuals between ages one and three years, we suggest nitazoxanide (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) and for individuals less than 12 months of age, we suggest metronidazole (<a class="graphic graphic_algorithm graphicRef139552" href="/z/d/graphic/139552.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent1">Other alternative agents include <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> and <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">mebendazole</a>, <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a>, furazolidone, quinacrine, <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">secnidazole</a>, and ornidazole (<a class="graphic graphic_table graphicRef61810" href="/z/d/graphic/61810.html" rel="external">table 1</a>). (See <a class="local">'Symptomatic individuals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnant and lactating individuals </strong>– During the first trimester, it is reasonable to defer therapy of mild giardiasis to minimize the risk of adverse drug effects for the fetus. For those whose symptoms warrant treatment during the first trimester and for those with mild disease in later trimesters, we suggest <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a>, which has limited systemic absorption (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For more severe disease in the second and third trimesters, we suggest <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Paromomycin is also an option for lactating individuals who do not want to interrupt breastfeeding for medication administration. (See <a class="local">'Pregnant and lactating individuals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expected response to therapy</strong> – Symptoms of acute giardiasis typically resolve within five to seven days of treatment, and parasites usually clear from the stool in this time frame. In those who had chronic symptoms (&gt;8 weeks) prior to treatment, symptoms may take several months to resolve. There is no need to repeat the stool examination to check for parasite clearance after symptom resolution. (See <a class="local">'Expected response to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent or recurrent symptoms</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation</strong> – Patients with recurrent or persistent symptoms should undergo a repeat stool examination (stool antigen or polymerase chain reaction) for detection of giardiasis and evaluation for potential sources of reinfection (eg, review of the exposure history, risk factors, and hygiene practices). For those with history suggestive of immune deficits or who have &gt;1 recurrence, evaluation for underlying immunodeficiency is also warranted. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of persistent or recurrent symptoms</strong> –<strong> </strong>For patients with persistent or recurrent symptoms, we reserve treatment for those with microbiologic confirmation of infection. Options include using the same agent, a different agent, or a combination, depending on prior treatment history. For patients with a negative stool assay, ongoing symptoms often have a noninfectious etiology. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventing transmission</strong> – This includes contact precautions for incontinent patients in institutional settings, strict adherence to hand hygiene with soap and water, and avoidance of recreational areas (eg, childcare centers, recreational water venues) until asymptomatic for 48 hours. (See <a class="local">'Counseling and prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H278768317"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Flor M Munoz, MD, MSc, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Minetti C, Chalmers RM, Beeching NJ, et al. Giardiasis. BMJ 2016; 355:i5369.</a></li><li><a class="nounderline abstract_t">Painter JE, Gargano JW, Collier SA, et al. Giardiasis surveillance -- United States, 2011-2012. MMWR Suppl 2015; 64:15.</a></li><li><a class="nounderline abstract_t">Torgerson PR, Devleesschauwer B, Praet N, et al. World Health Organization Estimates of the Global and Regional Disease Burden of 11 Foodborne Parasitic Diseases, 2010: A Data Synthesis. PLoS Med 2015; 12:e1001920.</a></li><li><a class="nounderline abstract_t">Ross AG, Olds GR, Cripps AW, et al. Enteropathogens and chronic illness in returning travelers. N Engl J Med 2013; 368:1817.</a></li><li><a class="nounderline abstract_t">Gardner TB, Hill DR. Treatment of giardiasis. Clin Microbiol Rev 2001; 14:114.</a></li><li><a class="nounderline abstract_t">Bartlett AV, Englender SJ, Jarvis BA, et al. Controlled trial of Giardia lamblia: control strategies in day care centers. Am J Public Health 1991; 81:1001.</a></li><li class="breakAll">American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.</li><li><a class="nounderline abstract_t">Ordóñez-Mena JM, McCarthy ND, Fanshawe TR. Comparative efficacy of drugs for treating giardiasis: a systematic update of the literature and network meta-analysis of randomized clinical trials. J Antimicrob Chemother 2018; 73:596.</a></li><li><a class="nounderline abstract_t">Tinidazole (Tindamax) - a new anti-protozoal drug. Med Lett Drugs Ther 2004; 46:70.</a></li><li class="breakAll">Presutti antiprotozoal agent Tindamax clears FDA; AWP is $18 per dose. In: "The Pink Sheet" vol 66, F-D-C Reports, Inc. Chevy Chase, MD 2004. p.10.</li><li><a class="nounderline abstract_t">Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 2005; 27:1859.</a></li><li><a class="nounderline abstract_t">Pasupuleti V, Escobedo AA, Deshpande A, et al. Efficacy of 5-nitroimidazoles for the treatment of giardiasis: a systematic review of randomized controlled trials. PLoS Negl Trop Dis 2014; 8:e2733.</a></li><li><a class="nounderline abstract_t">Escobedo AA, Alvarez G, González ME, et al. The treatment of giardiasis in children: single-dose tinidazole compared with 3 days of nitazoxanide. Ann Trop Med Parasitol 2008; 102:199.</a></li><li><a class="nounderline abstract_t">Jokipii L, Jokipii AM. Single-dose metronidazole and tinidazole as therapy for giardiasis: success rates, side effects, and drug absorption and elimination. J Infect Dis 1979; 140:984.</a></li><li><a class="nounderline abstract_t">Cañete R, Escobedo AA, González ME, et al. A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children. Curr Med Res Opin 2006; 22:2131.</a></li><li class="breakAll">Bartelt LA, Nash TE. Giardia lamblia. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed, Bennett JE, Dolin R, Blaser MJ (Eds), Elsevier Saunders, Philadelphia 2019. p.3154.</li><li class="breakAll">Romark Alinia adult dose 'approvable'; anti-parasitic approved for children. In: "The Pink Sheet," Vol 64, No 48, F-D-C Reports, Inc, Chevy Chase, MD 2002. p.11.</li><li><a class="nounderline abstract_t">Ortiz JJ, Ayoub A, Gargala G, et al. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001; 15:1409.</a></li><li><a class="nounderline abstract_t">Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001; 184:381.</a></li><li><a class="nounderline abstract_t">Davila-Gutierrez CE, Vasquez C, Trujillo-Hernandez B, Huerta M. Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am J Trop Med Hyg 2002; 66:251.</a></li><li><a class="nounderline abstract_t">Rossignol JF, Lopez-Chegne N, Julcamoro LM, et al. Nitazoxanide for the empiric treatment of pediatric infectious diarrhea. Trans R Soc Trop Med Hyg 2012; 106:167.</a></li><li><a class="nounderline abstract_t">Diaz E, Mondragon J, Ramirez E, Bernal R. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg 2003; 68:384.</a></li><li><a class="nounderline abstract_t">Nitazoxanide (Alinia)--a new anti-protozoal agent. Med Lett Drugs Ther 2003; 45:29.</a></li><li><a class="nounderline abstract_t">Cohen SA. Use of nitazoxanide as a new therapeutic option for persistent diarrhea: a pediatric perspective. Curr Med Res Opin 2005; 21:999.</a></li><li><a class="nounderline abstract_t">Chandy E, McCarthy J. Evidence behind the WHO guidelines: Hospital care for children: What is the most appropriate treatment for giardiasis? J Trop Pediatr 2009; 55:5.</a></li><li class="breakAll">Drugs for Parasitic Infections, 3rd ed, The Medical Letter, New Rochelle, NY 2013.</li><li><a class="nounderline abstract_t">Hall A, Nahar Q. Albendazole as a treatment for infections with Giardia duodenalis in children in Bangladesh. Trans R Soc Trop Med Hyg 1993; 87:84.</a></li><li><a class="nounderline abstract_t">Misra PK, Kumar A, Agarwal V, Jagota SC. A comparative clinical trial of albendazole versus metronidazole in giardiasis. Indian Pediatr 1995; 32:291.</a></li><li><a class="nounderline abstract_t">Dutta AK, Phadke MA, Bagade AC, et al. A randomised multicentre study to compare the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children. Indian J Pediatr 1994; 61:689.</a></li><li><a class="nounderline abstract_t">Solaymani-Mohammadi S, Genkinger JM, Loffredo CA, Singer SM. A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis. PLoS Negl Trop Dis 2010; 4:e682.</a></li><li><a class="nounderline abstract_t">Mejia R, Vicuña Y, Broncano N, et al. A novel, multi-parallel, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations. Am J Trop Med Hyg 2013; 88:1041.</a></li><li><a class="nounderline abstract_t">Canete R, Escobedo AA, Gonzalez ME, Almirall P. Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children. World J Gastroenterol 2006; 12:6366.</a></li><li><a class="nounderline abstract_t">Escobedo AA, Cañete R, Gonzalez ME, et al. A randomized trial comparing mebendazole and secnidazole for the treatment of giardiasis. Ann Trop Med Parasitol 2003; 97:499.</a></li><li><a class="nounderline abstract_t">Escobedo AA, Almirall P, González-Fraile E, Ballesteros J. Efficacy of mebendazole in paediatric patients with giardiasis: A systematic review and meta-analysis. Acta Trop 2018; 188:50.</a></li><li><a class="nounderline abstract_t">Cañete R, Brito K, Brito I, et al. Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials. Curr Ther Res Clin Exp 2018; 89:43.</a></li><li><a class="nounderline abstract_t">Sadjjadi SM, Alborzi AW, Mostovfi H. Comparative clinical trial of mebendazole and metronidazole in giardiasis of children. J Trop Pediatr 2001; 47:176.</a></li><li><a class="nounderline abstract_t">Pengsaa K, Sirivichayakul C, Pojjaroen-anant C, et al. Albendazole treatment for Giardia intestinalis infections in school children. Southeast Asian J Trop Med Public Health 1999; 30:78.</a></li><li><a class="nounderline abstract_t">Lalle M. Giardiasis in the post genomic era: treatment, drug resistance and novel therapeutic perspectives. Infect Disord Drug Targets 2010; 10:283.</a></li><li><a class="nounderline abstract_t">Craft JC, Murphy T, Nelson JD. Furazolidone and quinacrine. Comparative study of therapy for giardiasis in children. Am J Dis Child 1981; 135:164.</a></li><li><a class="nounderline abstract_t">Requena-Méndez A, Goñi P, Rubio E, et al. The Use of Quinacrine in Nitroimidazole-resistant Giardia Duodenalis: An Old Drug for an Emerging Problem. J Infect Dis 2017; 215:946.</a></li><li><a class="nounderline abstract_t">Neumayr A, Schunk M, Theunissen C, et al. Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: A TropNet Study. Clin Infect Dis 2021; 73:1517.</a></li><li><a class="nounderline abstract_t">Ozbilgin A, Ertan P, Yereli K, et al. Giardiasis treatment in Turkish children with a single dose of ornidazole. Scand J Infect Dis 2002; 34:918.</a></li><li><a class="nounderline abstract_t">Bassily S, Farid Z, el-Masry NA, Mikhail EM. Treatment of intestinal E. histolytica and G. lamblia with metronidazole, tinidazole and ornidazole: a comparative study. J Trop Med Hyg 1987; 90:9.</a></li><li class="breakAll">TOXNET: LactMed. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACTMED (Accessed on October 16, 2017).</li><li class="breakAll">US National Library of Medicine. TOXNET Databases. https://toxnet.nlm.nih.gov/ (Accessed on October 31, 2017).</li><li><a class="nounderline abstract_t">Nash TE, Ohl CA, Thomas E, et al. Treatment of patients with refractory giardiasis. Clin Infect Dis 2001; 33:22.</a></li><li><a class="nounderline abstract_t">van den Bijllaardt W, Overdevest IT, Buiting AG, Verweij JJ. Rapid clearance of Giardia lamblia DNA from the gut after successful treatment. Clin Microbiol Infect 2014; 20:O972.</a></li><li><a class="nounderline abstract_t">Escobedo AA, Hanevik K, Almirall P, et al. Management of chronic Giardia infection. Expert Rev Anti Infect Ther 2014; 12:1143.</a></li><li><a class="nounderline abstract_t">Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis 2017; 65:e45.</a></li><li><a class="nounderline abstract_t">Abboud P, Lemée V, Gargala G, et al. Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 32:1792.</a></li><li><a class="nounderline abstract_t">Gascón J, Abós R, Valls ME, Corachán M. Mebendazole and metronidazole in giardial infections. Trans R Soc Trop Med Hyg 1990; 84:694.</a></li><li><a class="nounderline abstract_t">Granados CE, Reveiz L, Uribe LG, Criollo CP. Drugs for treating giardiasis. Cochrane Database Syst Rev 2012; 12:CD007787.</a></li><li><a class="nounderline abstract_t">Murphy TV, Nelson JD. Five v ten days' therapy with furazolidone for giardiasis. Am J Dis Child 1983; 137:267.</a></li><li><a class="nounderline abstract_t">Mørch K, Hanevik K, Robertson LJ, et al. Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway. J Infect 2008; 56:268.</a></li><li><a class="nounderline abstract_t">Goldin AJ, Hall A, Sarker RN, et al. Diagnosis of Giardia duodenalis infection in Bangladeshi infants: faecal antigen capture ELISA. Trans R Soc Trop Med Hyg 1993; 87:428.</a></li><li><a class="nounderline abstract_t">Cacopardo B, Patamia I, Bonaccorso V, et al. [Synergic effect of albendazole plus metronidazole association in the treatment of metronidazole-resistant giardiasis]. Clin Ter 1995; 146:761.</a></li><li><a class="nounderline abstract_t">Meltzer E, Lachish T, Schwartz E. Treatment of giardiasis after nonresponse to nitroimidazole. Emerg Infect Dis 2014; 20:1742.</a></li><li><a class="nounderline abstract_t">Ydsten KA, Hellgren U, Asgeirsson H. Quinacrine Treatment of Nitroimidazole-Refractory Giardiasis. J Infect Dis 2022; 225:1773.</a></li><li><a class="nounderline abstract_t">Hanevik K, Hausken T, Morken MH, et al. Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection. J Infect 2007; 55:524.</a></li><li><a class="nounderline abstract_t">Hanevik K, Mørch K, Eide GE, et al. Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: a randomized open clinical trial. Scand J Infect Dis 2008; 40:517.</a></li><li><a class="nounderline abstract_t">Besirbellioglu BA, Ulcay A, Can M, et al. Saccharomyces boulardii and infection due to Giardia lamblia. Scand J Infect Dis 2006; 38:479.</a></li><li><a class="nounderline abstract_t">Morken MH, Valeur J, Norin E, et al. Antibiotic or bacterial therapy in post-giardiasis irritable bowel syndrome. Scand J Gastroenterol 2009; 44:1296.</a></li><li><a class="nounderline abstract_t">Argüello-García R, Cruz-Soto M, Romero-Montoya L, Ortega-Pierres G. Variability and variation in drug susceptibility among Giardia duodenalis isolates and clones exposed to 5-nitroimidazoles and benzimidazoles in vitro. J Antimicrob Chemother 2004; 54:711.</a></li><li><a class="nounderline abstract_t">Minenoa T, Avery MA. Giardiasis: recent progress in chemotherapy and drug development. Curr Pharm Des 2003; 9:841.</a></li><li><a class="nounderline abstract_t">Nabarro LE, Lever RA, Armstrong M, Chiodini PL. Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008-2013. Clin Microbiol Infect 2015; 21:791.</a></li><li><a class="nounderline abstract_t">Lemée V, Zaharia I, Nevez G, et al. Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France. J Antimicrob Chemother 2000; 46:819.</a></li><li><a class="nounderline abstract_t">Farbey MD, Reynoldson JA, Thompson RC. In vitro drug susceptibility of 29 isolates of Giardia duodenalis from humans as assessed by an adhesion assay. Int J Parasitol 1995; 25:593.</a></li><li><a class="nounderline abstract_t">Muñoz Gutiérrez J, Aldasoro E, Requena A, et al. Refractory giardiasis in Spanish travellers. Travel Med Infect Dis 2013; 11:126.</a></li><li><a class="nounderline abstract_t">Carter ER, Nabarro LE, Hedley L, Chiodini PL. Nitroimidazole-refractory giardiasis: a growing problem requiring rational solutions. Clin Microbiol Infect 2018; 24:37.</a></li><li><a class="nounderline abstract_t">Leitsch D. Drug Resistance in the Microaerophilic Parasite Giardia lamblia. Curr Trop Med Rep 2015; 2:128.</a></li><li><a class="nounderline abstract_t">El Mansoury ST, Abou El Naga IF, Negm AY, Amer EE. Influence of temperature and salinity on the viability and infectivity of Giardia lamblia and Cryptosporidia parvum. J Egypt Soc Parasitol 2004; 34:161.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. Parasites - Giardia. Prevention &amp; Control: General Public. https://www.cdc.gov/parasites/giardia/prevention-control-general-public.html (Accessed on August 30, 2018).</li><li><a class="nounderline abstract_t">Ongerth JE, Johnson RL, Macdonald SC, et al. Back-country water treatment to prevent giardiasis. Am J Public Health 1989; 79:1633.</a></li><li><a class="nounderline abstract_t">Adams DA, Thomas KR, Jajosky RA, et al. Summary of Notifiable Infectious Diseases and Conditions - United States, 2015. MMWR Morb Mortal Wkly Rep 2017; 64:1.</a></li><li><a class="nounderline abstract_t">Lin A, Ercumen A, Benjamin-Chung J, et al. Effects of Water, Sanitation, Handwashing, and Nutritional Interventions on Child Enteric Protozoan Infections in Rural Bangladesh: A Cluster-Randomized Controlled Trial. Clin Infect Dis 2018; 67:1515.</a></li><li><a class="nounderline abstract_t">Gilman RH, Marquis GS, Miranda E, et al. Rapid reinfection by Giardia lamblia after treatment in a hyperendemic Third World community. Lancet 1988; 1:343.</a></li><li><a class="nounderline abstract_t">Nayak N, Ganguly NK, Walia BN, et al. Specific secretory IgA in the milk of Giardia lamblia-infected and uninfected women. J Infect Dis 1987; 155:724.</a></li><li><a class="nounderline abstract_t">Rogawski ET, Bartelt LA, Platts-Mills JA, et al. Determinants and Impact of Giardia Infection in the First 2 Years of Life in the MAL-ED Birth Cohort. J Pediatric Infect Dis Soc 2017; 6:153.</a></li><li><a class="nounderline abstract_t">Mahmud MA, Chappell CL, Hossain MM, et al. Impact of breast-feeding on Giardia lamblia infections in Bilbeis, Egypt. Am J Trop Med Hyg 2001; 65:257.</a></li><li class="breakAll">United Nations Children's Fund (UNICEF). Improving Young Children’s Diets During the Complementary Feeding Period. UNICEF Programming Guidance. UNICEF; NY 2020.</li><li class="breakAll">United Nations Children's Fund (UNICEF). Programming Guidance: Nutrition in Middle Childhood and Adolescence. UNICEF; NY 2020.</li><li><a class="nounderline abstract_t">Lima AA, Soares AM, Lima NL, et al. Effects of vitamin A supplementation on intestinal barrier function, growth, total parasitic, and specific Giardia spp infections in Brazilian children: a prospective randomized, double-blind, placebo-controlled trial. J Pediatr Gastroenterol Nutr 2010; 50:309.</a></li><li><a class="nounderline abstract_t">Long KZ, Rosado JL, Montoya Y, et al. Effect of vitamin A and zinc supplementation on gastrointestinal parasitic infections among Mexican children. Pediatrics 2007; 120:e846.</a></li><li><a class="nounderline abstract_t">Veenemans J, Schouten LR, Ottenhof MJ, et al. Effect of preventive supplementation with zinc and other micronutrients on non-malarial morbidity in Tanzanian pre-school children: a randomized trial. PLoS One 2012; 7:e41630.</a></li></ol></div><div id="topicVersionRevision">Topic 6024 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27789441" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Giardiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25928582" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Giardiasis surveillance -- United States, 2011-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26633705" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : World Health Organization Estimates of the Global and Regional Disease Burden of 11 Foodborne Parasitic Diseases, 2010: A Data Synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23656647" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Enteropathogens and chronic illness in returning travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148005" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment of giardiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1853990" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Controlled trial of Giardia lamblia: control strategies in day care centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1853990" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Controlled trial of Giardia lamblia: control strategies in day care centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29186570" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparative efficacy of drugs for treating giardiasis: a systematic update of the literature and network meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15375353" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tinidazole (Tindamax) - a new anti-protozoal drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15375353" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Tinidazole (Tindamax) - a new anti-protozoal drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507373" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Tinidazole: a nitroimidazole antiprotozoal agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24625554" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy of 5-nitroimidazoles for the treatment of giardiasis: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18348774" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The treatment of giardiasis in children: single-dose tinidazole compared with 3 days of nitazoxanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/541526" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Single-dose metronidazole and tinidazole as therapy for giardiasis: success rates, side effects, and drug absorption and elimination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17076973" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17076973" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17076973" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11552913" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443569" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12139216" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22301075" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nitazoxanide for the empiric treatment of pediatric infectious diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12875284" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12717338" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nitazoxanide (Alinia)--a new anti-protozoal agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16004666" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Use of nitazoxanide as a new therapeutic option for persistent diarrhea: a pediatric perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18786986" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evidence behind the WHO guidelines: Hospital care for children: What is the most appropriate treatment for giardiasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18786986" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Evidence behind the WHO guidelines: Hospital care for children: What is the most appropriate treatment for giardiasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8465408" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Albendazole as a treatment for infections with Giardia duodenalis in children in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8613282" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A comparative clinical trial of albendazole versus metronidazole in giardiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7721374" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A randomised multicentre study to compare the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20485492" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23509117" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A novel, multi-parallel, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17072963" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930613" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A randomized trial comparing mebendazole and secnidazole for the treatment of giardiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30092225" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of mebendazole in paediatric patients with giardiasis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30792825" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11419683" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparative clinical trial of mebendazole and metronidazole in giardiasis of children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10695793" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Albendazole treatment for Giardia intestinalis infections in school children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20429863" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Giardiasis in the post genomic era: treatment, drug resistance and novel therapeutic perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7468550" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Furazolidone and quinacrine. Comparative study of therapy for giardiasis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28453841" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The Use of Quinacrine in Nitroimidazole-resistant Giardia Duodenalis: An Old Drug for an Emerging Problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34115100" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: A TropNet Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12587625" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Giardiasis treatment in Turkish children with a single dose of ornidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3546716" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment of intestinal E. histolytica and G. lamblia with metronidazole, tinidazole and ornidazole: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3546716" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment of intestinal E. histolytica and G. lamblia with metronidazole, tinidazole and ornidazole: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3546716" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment of intestinal E. histolytica and G. lamblia with metronidazole, tinidazole and ornidazole: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389490" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Treatment of patients with refractory giardiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24655130" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rapid clearance of Giardia lamblia DNA from the gut after successful treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25059638" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Management of chronic Giardia infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29053792" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11360222" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2278074" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Mebendazole and metronidazole in giardial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235648" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Drugs for treating giardiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6823925" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Five v ten days' therapy with furazolidone for giardiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18328567" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8249073" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diagnosis of Giardia duodenalis infection in Bangladeshi infants: faecal antigen capture ELISA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8681495" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : [Synergic effect of albendazole plus metronidazole association in the treatment of metronidazole-resistant giardiasis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25271363" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of giardiasis after nonresponse to nitroimidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34036328" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Quinacrine Treatment of Nitroimidazole-Refractory Giardiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17964658" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18584540" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: a randomized open clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16798698" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Saccharomyces boulardii and infection due to Giardia lamblia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821794" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Antibiotic or bacterial therapy in post-giardiasis irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15347633" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Variability and variation in drug susceptibility among Giardia duodenalis isolates and clones exposed to 5-nitroimidazoles and benzimidazoles in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12678869" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Giardiasis: recent progress in chemotherapy and drug development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25975511" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11062206" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7635637" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : In vitro drug susceptibility of 29 isolates of Giardia duodenalis from humans as assessed by an adhesion assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23218784" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Refractory giardiasis in Spanish travellers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28624613" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Nitroimidazole-refractory giardiasis: a growing problem requiring rational solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26258002" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Drug Resistance in the Microaerophilic Parasite Giardia lamblia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15125524" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Influence of temperature and salinity on the viability and infectivity of Giardia lamblia and Cryptosporidia parvum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15125524" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Influence of temperature and salinity on the viability and infectivity of Giardia lamblia and Cryptosporidia parvum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2817191" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Back-country water treatment to prevent giardiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28796757" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Summary of Notifiable Infectious Diseases and Conditions - United States, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29669039" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effects of Water, Sanitation, Handwashing, and Nutritional Interventions on Child Enteric Protozoan Infections in Rural Bangladesh: A Cluster-Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2893149" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Rapid reinfection by Giardia lamblia after treatment in a hyperendemic Third World community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3819477" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Specific secretory IgA in the milk of Giardia lamblia-infected and uninfected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28204556" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Determinants and Impact of Giardia Infection in the First 2 Years of Life in the MAL-ED Birth Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561714" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Impact of breast-feeding on Giardia lamblia infections in Bilbeis, Egypt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561714" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Impact of breast-feeding on Giardia lamblia infections in Bilbeis, Egypt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561714" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Impact of breast-feeding on Giardia lamblia infections in Bilbeis, Egypt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20038852" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effects of vitamin A supplementation on intestinal barrier function, growth, total parasitic, and specific Giardia spp infections in Brazilian children: a prospective randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908741" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effect of vitamin A and zinc supplementation on gastrointestinal parasitic infections among Mexican children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22870238" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of preventive supplementation with zinc and other micronutrients on non-malarial morbidity in Tanzanian pre-school children: a randomized trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
